Effect of lumbar spinal stenosis on bone mineral density in osteoporosis patients treated with ibandronate
| Autor: | Hyung-Youl Park, Jun-Seok Lee, Soo-Bin Park, Ki-Won Kim, Ji-Yoon Ha, In-Hwa Baek |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty Sports medicine Osteoporosis Urology Diseases of the musculoskeletal system 03 medical and health sciences 0302 clinical medicine Spinal Stenosis Rheumatology Bone Density Internal medicine Epidemiology medicine Bone mineral density Humans Orthopedics and Sports Medicine Risk factor Ibandronic Acid Bone mineral 030222 orthopedics Lumbar Vertebrae Bone Density Conservation Agents Diphosphonates business.industry Research Lumbar spinal stenosis medicine.disease Treatment Outcome RC925-935 Orthopedic surgery Ibandronate business 030217 neurology & neurosurgery |
| Zdroj: | BMC Musculoskeletal Disorders BMC Musculoskeletal Disorders, Vol 22, Iss 1, Pp 1-7 (2021) |
| ISSN: | 1471-2474 |
| Popis: | Background Lumbar spinal stenosis (LSS) can cause various neurological symptoms and reduce the daily activity of patients. Many studies have shown that free physical activities and exercise can improve bone mineral density (BMD) in patients with osteoporosis. However, the effect of LSS on BMD has not been reported. The purpose of this study was to investigate the effects of LSS on BMD in patients treated with ibandronate for newly diagnosed osteoporosis. Methods Group 1 included 83 patients treated for osteoporosis alone, and group 2 included 76 patients treated for both osteoporosis and symptomatic LSS. We confirmed four BMD values presented as T-score at initial, and 1-, 2-, and 3-year follow-ups. Mean BMD and annual changes of BMD for three years were compared between the two groups. Correlations between initial BMD and total change of BMD, and related factors for continuous BMD improvement for three years were also evaluated. Results Mean annual BMDs were significantly higher in group 1 compared than in group 2 (-3.39 vs. -3.58 at 1-year; -3.27 vs. -3.49 at 2-year; -3.13 vs. -3.45 at 3-year; all p p = 0.036) and total change of BMD for three years (0.57 vs. 0.35, p = 0.002) were significantly higher in group 1. Group 1 had a strong negative correlation (r = -0.511, P = 0.000) between initial BMD and total change of BMD, whereas group 2 showed a weak negative correlation (r = -0.247, p = 0.032). In multivariate analysis, symptomatic LSS was the only independent risk factor for continuous BMD improvement (Odds ratio = 0.316, p = 0.001). Conclusions Symptomatic LSS may interfere with BMD improvement in the treatment of osteoporosis with ibandronate. Active treatment for LSS with more potent treatment for osteoporosis should be taken to increase BMD for patients with osteoporosis and LSS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|